PRPeptide Evidence ReferenceEVIDENCE-GRADED · EDUCATIONAL
Educational reference only — not medical advice. Nothing is sold on this site. Research compounds are not for human use.
Home>>Peptides>>Retatrutide>>side-effects
Clinical-stage

Retatrutide Side Effects: What Is Known So Far

The safety database for retatrutide today consists of its phase 2 trial and early phase 3 disclosures. This page summarizes what has been reported — and what cannot yet be known.

Reported in trials to date

Dose-related gastrointestinal effects — nausea, vomiting, diarrhea — have been the dominant adverse events, with intensity tracking the escalation schedule, consistent with the incretin class.

Class-legacy questions

Gallbladder events, pancreatitis, and long-term safety in specific populations are standing questions for the whole class; for retatrutide they are being characterized in ongoing trials rather than settled by them.

Glucagon-specific questions

The triple-agonist glucagon component adds theoretical questions (hepatic and glucose effects) that dual agonists do not carry — precisely the kind of question trials exist to answer.

What no one can claim

Any "side effect profile" circulating for retatrutide outside trial reports is not data. The compound is not approved, not quality-controlled outside trial supply, and not safe to self-administer under any framework.

Educational content only — not medical advice. This compound is not an approved medicine; no dosing guidance is or will be provided.

References

  1. ClinicalTrials.gov — registered retatrutide studies. [source]
  2. Newman JC, et al. Retatrutide phase 2 results. N Engl J Med 2023 (see trial record for details). [source]
EM
Dr. Elena Marsh, PhDMolecular Pharmacology · Lead Editor

Written and maintained by the editorial team. Medically reviewed by Dr. James Okafor, MD (Internal Medicine).

Evidence tier: Clinical-stage · Last reviewed: 2026-09-05 · Sources cited below.

Advertisement